Carl H. June
for the development of chimeric antigen receptor T cell immunotherapy whereby the patient's T cells are modified to target and kill cancer cells.
Recognition for work with lasting impact
for the development of chimeric antigen receptor T cell immunotherapy whereby the patient's T cells are modified to target and kill cancer cells.